Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Lung Neoplasms 1371Carcinoma, Non-Small-Cell Lung 1080Breast Neoplasms 183Neoplasms 145Small Cell Lung Carcinoma 137Colorectal Neoplasms 104Adenocarcinoma of Lung 87Melanoma 84Prostatic Neoplasms 80Pancreatic Neoplasms 79Esophageal Neoplasms 70Head and Neck Neoplasms 69Ovarian Neoplasms 67Colonic Neoplasms 67Stomach Neoplasms 63Urinary Bladder Neoplasms 49Neoplasm Metastasis 49Disease 49Mesothelioma 44Liver Neoplasms 44Pulmonary Disease, Chronic Obstructive 42Mesothelioma, Malignant 42Brain Neoplasms 37Lung Diseases 36Carcinoma, Renal Cell 35Uterine Cervical Neoplasms 34Pleural Effusion, Malignant 34Kidney Neoplasms 33NSCLC 31Carcinoma 28

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Hyperlipidemias × Thoracic × Clear all
NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Peking University Third Hospital

Enrolling by invitation
167 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡